UCB's Global Corporate Website
Welcome to UCB in the United States
  • Healthcare Professionals
  • Patients
  • Investors
  • Dec

    02

    UCB presents new data about the real-world experience of FINTEPLA® (fenfluramine) and rare epilepsy syndromes at 2023 American Epilepsy Society (AES) Annual Meeting

    Dec

    01

    UCB presents new data advancing patient-focused scientific leadership at American Epilepsy Society Annual Meeting

    Dec

    01

    Media Statement on levetiracetam (KEPPRA® and KEPPRA XR®) and DRESS

    Nov

    29

    Delivering Meaningful and Accessible Innovation for People Living with Severe Diseases

    Nov

    27

    UCB's Commitment to Diversity, Equity, and Inclusion: Partnering at AES for a Better Future

    Nov

    17

    Employee Spotlight: Stephen Mayclin’s Impact as a Working for Cures Champion and R&D Advocate

    Nov

    14

    UCB Announces U.S. Availability of BIMZELX® for the Treatment of Adults with Moderate-to-Severe Plaque Psoriasis

    Nov

    11

    Post Hoc Analysis Showed CIMZIA® (Certolizumab Pegol) Resulted in Meaningful Efficacy for RA Patients with High Levels of Rheumatoid Factor (RF)

    Nov

    10

    UCB Presents New Five-Year Data on BIMZELX® (bimekizumab-bkzx) in Ankylosing Spondylitis at ACR Convergence 2023

    Nov

    09

    Advancing Rheumatic Disease Treatment